An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
Video An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA -Copyright ©2023 by PanNash™ Initiative - All rights reserved.
- Prof. M. F. Abdelmalek
- May 10, 2019
- More Epidemiology
Would you like to read more?
Prof. M. F. Abdelmalek
Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase…
Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases,…
Machine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of…
Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up…
Research Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care
Both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), NAFLD’s inflammatory and progressive subtype, are the histologic manifestations of…
Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
NAFLD and Cardiovascular Diseases: What is The Link?
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through…
Lifestyle interventions in NAFLD: what does the evidence say?
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis…
NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection…
NAFLD and New-Onset Heart Failure: What is the Link?
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
